SG10201607813SA - Compounds and methods for kinase modulation, and indications therefor - Google Patents
Compounds and methods for kinase modulation, and indications thereforInfo
- Publication number
- SG10201607813SA SG10201607813SA SG10201607813SA SG10201607813SA SG10201607813SA SG 10201607813S A SG10201607813S A SG 10201607813SA SG 10201607813S A SG10201607813S A SG 10201607813SA SG 10201607813S A SG10201607813S A SG 10201607813SA SG 10201607813S A SG10201607813S A SG 10201607813SA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- methods
- kinase modulation
- indications therefor
- indications
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261612912P | 2012-03-19 | 2012-03-19 | |
US201361754318P | 2013-01-18 | 2013-01-18 | |
US13/802,106 US9358235B2 (en) | 2012-03-19 | 2013-03-13 | Kinase modulation, and indications therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201607813SA true SG10201607813SA (en) | 2016-11-29 |
Family
ID=48045777
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201405764YA SG11201405764YA (en) | 2012-03-19 | 2013-03-18 | Compounds and methods for kinase modulation, and indications therefor |
SG10201607813SA SG10201607813SA (en) | 2012-03-19 | 2013-03-18 | Compounds and methods for kinase modulation, and indications therefor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201405764YA SG11201405764YA (en) | 2012-03-19 | 2013-03-18 | Compounds and methods for kinase modulation, and indications therefor |
Country Status (16)
Country | Link |
---|---|
US (3) | US9358235B2 (fr) |
EP (2) | EP2827904A1 (fr) |
JP (1) | JP6165837B2 (fr) |
KR (2) | KR20140144229A (fr) |
CN (1) | CN104703623B (fr) |
AU (2) | AU2013235298A1 (fr) |
BR (1) | BR112014023162A8 (fr) |
CA (1) | CA2867918C (fr) |
EA (1) | EA029676B1 (fr) |
HK (1) | HK1204995A1 (fr) |
IL (1) | IL234702A (fr) |
MY (1) | MY176903A (fr) |
NZ (1) | NZ630483A (fr) |
SG (2) | SG11201405764YA (fr) |
WO (1) | WO2013142427A1 (fr) |
ZA (1) | ZA201407580B (fr) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063888A2 (fr) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées |
CN101808994B (zh) | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
MA33028B1 (fr) | 2009-04-03 | 2012-02-01 | Plexxikon Inc | Compositions et utilisations associees |
CN102695417A (zh) | 2009-11-06 | 2012-09-26 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
MY156210A (en) | 2009-11-18 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
JP5815558B2 (ja) | 2009-12-23 | 2015-11-17 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼ調節のための化合物及び方法ならびにそれらの適応症 |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
BR112013020041B1 (pt) | 2011-02-07 | 2021-11-23 | Plexxikon, Inc | Compostos e composições para a modulação de quinases e uso dos mesmos |
AU2012255275B2 (en) | 2011-05-17 | 2016-01-28 | Plexxikon Inc. | Kinase modulation and indications therefor |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
MX2015002887A (es) | 2012-09-06 | 2015-07-06 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello. |
KR102212923B1 (ko) | 2012-12-21 | 2021-02-04 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
MX2015012456A (es) | 2013-03-15 | 2016-02-03 | Plexxikon Inc | Compuestos heterociclicos y usos de los mismos. |
EP3004060B1 (fr) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Composés pour modulation de kinases, et indications correspondantes |
CN104710417B (zh) * | 2013-12-11 | 2020-09-08 | 上海科州药物研发有限公司 | 氮杂吲哚类衍生物及其合成方法 |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2015164862A1 (fr) * | 2014-04-25 | 2015-10-29 | Memorial Sloan-Kettering Cancer Center | Traitement de tumeurs provoquées par h-ras |
AR101106A1 (es) | 2014-07-02 | 2016-11-23 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton |
CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
WO2016044067A1 (fr) | 2014-09-15 | 2016-03-24 | Plexxikon Inc. | Composés hétérocycliques et leurs utilisations |
WO2016164641A1 (fr) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Composés et méthodes de modulation des kinases, et leurs indications |
JP6946194B2 (ja) | 2015-05-06 | 2021-10-06 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節する化合物の固体形態 |
JP6530826B2 (ja) | 2015-05-06 | 2019-06-12 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを修飾する1h−ピロロ[2,3−b]ピリジン誘導体の合成 |
BR112017025045A2 (pt) | 2015-05-22 | 2018-08-07 | Plexxikon Inc | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 |
US9776998B2 (en) | 2015-05-22 | 2017-10-03 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
WO2016188816A1 (fr) * | 2015-05-22 | 2016-12-01 | Ucb Biopharma Sprl | Traitement de l'épilepsie |
EA039951B1 (ru) * | 2015-05-27 | 2022-03-31 | Юсб Биофарма Спрл | Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе |
CA2993018A1 (fr) * | 2015-07-20 | 2017-01-26 | Genzyme Corporation | Inhibiteurs du recepteur de facteur-1 de stimulation de colonies (csf-1r) |
WO2017019804A2 (fr) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Composés et procédés de modulation des kinases, et indications associées |
WO2017053243A1 (fr) | 2015-09-21 | 2017-03-30 | Plexxikon Inc. | Composés hétérocycliques et leurs utilisations |
CN105131013A (zh) * | 2015-10-18 | 2015-12-09 | 淄博夸克医药技术有限公司 | 一种新的大环内脂类化合物及其制备方法和医药用途 |
JP6862468B2 (ja) | 2015-12-07 | 2021-04-21 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼ調節のための化合物及び方法ならびにそのための指示 |
EP3824909A1 (fr) | 2016-03-02 | 2021-05-26 | Eisai R&D Management Co., Ltd. | Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation |
CA3017972C (fr) | 2016-03-16 | 2023-03-28 | Plexxikon Inc. | Composes et procedes de modulation de kinases et indications associees |
WO2018001270A1 (fr) * | 2016-06-30 | 2018-01-04 | Noratech Pharmaceuticals, Inc. | Promédicaments de palbociclib et leur composition |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
AU2017395023B2 (en) | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
AU2018237047A1 (en) | 2017-03-20 | 2019-10-17 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
EP3600322A1 (fr) * | 2017-03-28 | 2020-02-05 | Boehringer Ingelheim International GmbH | Nintedanib destiné à être utilisé dans des procédés de traitement de dystrophie musculaire |
WO2018182527A1 (fr) * | 2017-03-30 | 2018-10-04 | National University Of Singapore | Procédé de traitement de complications inflammatoires dans des maladies oculaires |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
AU2018307910A1 (en) | 2017-07-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Formulations of a compound modulating kinases |
CN109549941A (zh) * | 2017-09-26 | 2019-04-02 | 广西梧州制药(集团)股份有限公司 | 一种吡唑并嘧啶衍生物在制备治疗疾病药物方面的用途 |
CN109549940A (zh) * | 2017-09-26 | 2019-04-02 | 广西梧州制药(集团)股份有限公司 | 一种吡唑并嘧啶衍生物外用制剂及其制备方法 |
JP2020536917A (ja) | 2017-10-13 | 2020-12-17 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節するための化合物の固体形態 |
AU2018354423A1 (en) | 2017-10-27 | 2020-05-14 | Plexxikon Inc. | Formulations of a compound modulating kinases |
AU2019239952A1 (en) | 2018-03-20 | 2020-10-08 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
SG11202109997PA (en) * | 2019-03-29 | 2021-10-28 | Kowa Co | Novel azaindole derivative |
KR20220018475A (ko) | 2019-04-09 | 2022-02-15 | 플렉시콘 인코퍼레이티드 | Ep300 또는 cbp 조절 및 이의 표시를 위한 응축 아진 |
JP2022528780A (ja) * | 2019-04-12 | 2022-06-15 | ナショナル ヘルス リサーチ インスティトゥーツ | 治療的使用のためのキナーゼ阻害剤としての複素環式化合物 |
CN114981298A (zh) | 2019-12-12 | 2022-08-30 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
EP4139296A1 (fr) | 2020-04-23 | 2023-03-01 | Opna Immuno Oncology, SA | Composés et procédés de modulation de cd73 et leurs indications |
EP4178982A1 (fr) | 2020-07-13 | 2023-05-17 | Precirix N.V. | Fragment d'anticorps contre folr1 |
JP2023542473A (ja) | 2020-08-21 | 2023-10-10 | プレキシコン インコーポレーテッド | 併用薬抗がん治療 |
JP2024500919A (ja) | 2020-12-23 | 2024-01-10 | ジェンザイム・コーポレーション | 重水素化コロニー刺激因子-1受容体(csf-1r)阻害剤 |
KR20220133109A (ko) | 2021-03-24 | 2022-10-04 | 재단법인 아산사회복지재단 | 악성말초신경초종의 감별진단을 위한 조성물 |
WO2023179793A1 (fr) * | 2022-03-25 | 2023-09-28 | 成都嘉葆药银医药科技有限公司 | Forme cristalline d'un composé 1h-pyrrolo[2,3-c]pyridine et son procédé de préparation |
WO2023203135A1 (fr) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Anticorps radiomarqué amélioré |
WO2023213801A1 (fr) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pré-ciblage |
CN114736204A (zh) * | 2022-05-06 | 2022-07-12 | 湖北工业大学 | 一种培西达替尼结构类似物的制备方法及其抗肿瘤中的应用 |
CN115054592A (zh) * | 2022-07-06 | 2022-09-16 | 复旦大学附属中山医院 | 一种化合物在制备治疗增殖型肝细胞癌药物中的应用 |
CN115710281B (zh) * | 2022-11-14 | 2024-05-17 | 南京中医药大学 | 一种异噁唑并[5,4-b]吡啶类FLT3抑制剂及其制备方法与用途 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3191397A (en) | 1996-06-25 | 1998-01-14 | Takeda Chemical Industries Ltd. | Oxazolone derivatives and their use as anti-(helicobacter pylori) agent |
US20040171062A1 (en) | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
BR122012021252B8 (pt) | 2002-09-06 | 2021-05-25 | Cerulean Pharma Inc | polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência |
WO2004024895A2 (fr) | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Structure cristalline de la proteine kinase pim-1 |
US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
WO2004078923A2 (fr) | 2003-02-28 | 2004-09-16 | Plexxikon, Inc. | Structure cristalline de pyk2 et ses utilisations |
US20050079548A1 (en) | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
UA88767C2 (uk) | 2003-07-17 | 2009-11-25 | Плексікон, Інк. | Ppar активні сполуки |
WO2005028624A2 (fr) | 2003-09-15 | 2005-03-31 | Plexxikon, Inc. | Echafaudages moleculaires pour le developpement de ligands des proteines kinases |
ES2466818T3 (es) * | 2003-09-26 | 2014-06-11 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
US7517970B2 (en) | 2003-12-19 | 2009-04-14 | Plexxikon, Inc. | Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same |
US20070066641A1 (en) | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
CA2550361C (fr) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Composes et methodes de developpement de modulateurs de ret |
WO2006078287A2 (fr) | 2004-05-06 | 2006-07-27 | Plexxikon, Inc. | Inhibiteurs de pde4b |
TW200616632A (en) | 2004-06-17 | 2006-06-01 | Plexxikon Inc | Compounds modulating c-kit activity and uses therefor |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
NZ553267A (en) | 2004-07-27 | 2010-09-30 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators |
WO2006026754A2 (fr) | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Inhibiteurs de la phosphodiesterase 4b (pde4b) |
JP2008521829A (ja) | 2004-11-30 | 2008-06-26 | プレキシコン,インコーポレーテッド | Ppar活性化合物 |
US20060135540A1 (en) | 2004-11-30 | 2006-06-22 | Jack Lin | PPAR active compounds |
US20060160135A1 (en) | 2004-12-08 | 2006-07-20 | Weiru Wang | SF-1 and LRH-1 modulator development |
WO2006071966A2 (fr) * | 2004-12-29 | 2006-07-06 | The Brigham And Women's Hospital, Inc. | Composes de rapamycine traitant la neurofibromatose de type 1 |
US7846941B2 (en) | 2005-05-17 | 2010-12-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
AU2006287513A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1, 3-disubstituted indole derivatives for use as PPAR modulators |
TW200800872A (en) | 2005-09-07 | 2008-01-01 | Plexxikon Inc | PPAR active compounds |
CA2621275A1 (fr) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Composes actifs sur les ppar |
WO2008063888A2 (fr) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
WO2008079909A1 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Composés et méthodes de modulation des kinases, et indications connexes |
AU2007336811A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
CN101668737A (zh) | 2007-03-08 | 2010-03-10 | 普莱希科公司 | Ppar活性化合物 |
CN101808994B (zh) | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
WO2009152083A1 (fr) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | Dérivés 5h-pyrrolo-[2,3-b]-pyrazine destinés à la modulation de kinases, et des indications pour ceux-ci |
US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
AU2010224245B2 (en) | 2009-03-11 | 2016-07-21 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of Raf kinases |
KR20110130463A (ko) | 2009-03-11 | 2011-12-05 | 플렉시콘, 인코퍼레이티드 | Raf 키나제의 억제를 위한 피롤로[2,3-b]피리딘 유도체 |
WO2010111527A1 (fr) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines en tant qu'inhibiteurs de la kinase et leur utilisation médicale |
MA33028B1 (fr) | 2009-04-03 | 2012-02-01 | Plexxikon Inc | Compositions et utilisations associees |
CA2761009A1 (fr) | 2009-05-04 | 2010-11-11 | Plexxikon, Inc. | Composes et procedes pour inhiber la renine, et indications associees |
TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
CN102695417A (zh) | 2009-11-06 | 2012-09-26 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
MY156210A (en) | 2009-11-18 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
JP5815558B2 (ja) | 2009-12-23 | 2015-11-17 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼ調節のための化合物及び方法ならびにそれらの適応症 |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
US8642606B2 (en) | 2010-09-29 | 2014-02-04 | Plexxikon Inc. | ZAP-70 active compounds |
BR112013020041B1 (pt) | 2011-02-07 | 2021-11-23 | Plexxikon, Inc | Compostos e composições para a modulação de quinases e uso dos mesmos |
AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
AU2012255275B2 (en) | 2011-05-17 | 2016-01-28 | Plexxikon Inc. | Kinase modulation and indications therefor |
CN102993199A (zh) | 2011-09-09 | 2013-03-27 | 山东轩竹医药科技有限公司 | 杂环取代的吡啶并吡咯激酶抑制剂 |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
MX2015002887A (es) | 2012-09-06 | 2015-07-06 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello. |
KR102212923B1 (ko) | 2012-12-21 | 2021-02-04 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
MX2015012456A (es) | 2013-03-15 | 2016-02-03 | Plexxikon Inc | Compuestos heterociclicos y usos de los mismos. |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
EP3004060B1 (fr) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Composés pour modulation de kinases, et indications correspondantes |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2016044067A1 (fr) | 2014-09-15 | 2016-03-24 | Plexxikon Inc. | Composés hétérocycliques et leurs utilisations |
WO2016164641A1 (fr) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Composés et méthodes de modulation des kinases, et leurs indications |
JP6530826B2 (ja) | 2015-05-06 | 2019-06-12 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを修飾する1h−ピロロ[2,3−b]ピリジン誘導体の合成 |
JP6946194B2 (ja) | 2015-05-06 | 2021-10-06 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節する化合物の固体形態 |
BR112017025045A2 (pt) | 2015-05-22 | 2018-08-07 | Plexxikon Inc | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 |
US9776998B2 (en) | 2015-05-22 | 2017-10-03 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
WO2017019804A2 (fr) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Composés et procédés de modulation des kinases, et indications associées |
WO2017053243A1 (fr) | 2015-09-21 | 2017-03-30 | Plexxikon Inc. | Composés hétérocycliques et leurs utilisations |
JP6862468B2 (ja) | 2015-12-07 | 2021-04-21 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼ調節のための化合物及び方法ならびにそのための指示 |
CA3017972C (fr) | 2016-03-16 | 2023-03-28 | Plexxikon Inc. | Composes et procedes de modulation de kinases et indications associees |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
-
2013
- 2013-03-13 US US13/802,106 patent/US9358235B2/en active Active
- 2013-03-18 NZ NZ630483A patent/NZ630483A/en unknown
- 2013-03-18 EP EP13714152.9A patent/EP2827904A1/fr not_active Withdrawn
- 2013-03-18 JP JP2015501836A patent/JP6165837B2/ja active Active
- 2013-03-18 WO PCT/US2013/032835 patent/WO2013142427A1/fr active Application Filing
- 2013-03-18 MY MYPI2014702654A patent/MY176903A/en unknown
- 2013-03-18 EP EP23191645.3A patent/EP4295912A3/fr active Pending
- 2013-03-18 CN CN201380024796.8A patent/CN104703623B/zh active Active
- 2013-03-18 SG SG11201405764YA patent/SG11201405764YA/en unknown
- 2013-03-18 EA EA201491721A patent/EA029676B1/ru not_active IP Right Cessation
- 2013-03-18 BR BR112014023162A patent/BR112014023162A8/pt not_active Application Discontinuation
- 2013-03-18 KR KR1020147029231A patent/KR20140144229A/ko not_active IP Right Cessation
- 2013-03-18 CA CA2867918A patent/CA2867918C/fr active Active
- 2013-03-18 AU AU2013235298A patent/AU2013235298A1/en not_active Abandoned
- 2013-03-18 SG SG10201607813SA patent/SG10201607813SA/en unknown
- 2013-03-18 KR KR1020207033951A patent/KR102350088B1/ko active IP Right Grant
-
2014
- 2014-09-17 IL IL234702A patent/IL234702A/en active IP Right Grant
- 2014-10-17 ZA ZA2014/07580A patent/ZA201407580B/en unknown
-
2015
- 2015-06-23 HK HK15105961.7A patent/HK1204995A1/xx unknown
-
2016
- 2016-05-05 US US15/147,781 patent/US9730918B2/en active Active
-
2017
- 2017-08-04 US US15/669,353 patent/US10123998B2/en active Active
- 2017-10-30 AU AU2017254821A patent/AU2017254821B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2827904A1 (fr) | 2015-01-28 |
KR102350088B1 (ko) | 2022-01-12 |
ZA201407580B (en) | 2020-05-27 |
EA201491721A1 (ru) | 2015-02-27 |
CA2867918A1 (fr) | 2013-09-26 |
CN104703623A (zh) | 2015-06-10 |
CA2867918C (fr) | 2020-05-05 |
KR20140144229A (ko) | 2014-12-18 |
US20160243092A1 (en) | 2016-08-25 |
BR112014023162A2 (pt) | 2017-06-20 |
CN104703623B (zh) | 2017-06-23 |
NZ630483A (en) | 2017-08-25 |
AU2013235298A1 (en) | 2014-10-30 |
WO2013142427A1 (fr) | 2013-09-26 |
EP4295912A3 (fr) | 2024-03-06 |
US20180055828A1 (en) | 2018-03-01 |
EA029676B1 (ru) | 2018-04-30 |
EP4295912A2 (fr) | 2023-12-27 |
AU2017254821B2 (en) | 2019-09-19 |
KR20200139832A (ko) | 2020-12-14 |
JP2015510944A (ja) | 2015-04-13 |
AU2017254821A1 (en) | 2017-11-16 |
US20140037617A1 (en) | 2014-02-06 |
JP6165837B2 (ja) | 2017-07-19 |
HK1204995A1 (en) | 2015-12-11 |
BR112014023162A8 (pt) | 2018-01-16 |
US10123998B2 (en) | 2018-11-13 |
US9730918B2 (en) | 2017-08-15 |
MY176903A (en) | 2020-08-26 |
SG11201405764YA (en) | 2014-10-30 |
US9358235B2 (en) | 2016-06-07 |
IL234702A (en) | 2017-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181779T1 (hr) | Spojevi i postupci za modulaciju kinaze, te indikacije za njih | |
HK1213877A1 (zh) | 用於激酶調節的化合物和方法及其適應症 | |
HK1204995A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
HK1219732A1 (zh) | 用於激酶調節的化合物及其適應症 | |
EP2892534B8 (fr) | Composés et procédés pour la modulation des kinases, et leurs indications | |
ZA201207898B (en) | Compounds and methods for kinase modulation,and indications therefor | |
HK1199713A1 (en) | Kinase modulation and indications therefor | |
PT2906696T (pt) | Métodos para modular a expressão de c9orf72 | |
HK1209277A1 (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6- | |
GB201204383D0 (en) | H, level | |
GB201223020D0 (en) | Tmf | |
GB201213825D0 (en) | Damper-device for bouncing-device |